Sugi Predict

Sugi Predict / Compounds / SCHEMBL4548650

SCHEMBL4548650

SCHEMBL4548650

Cc1ccc2c(C)ncnc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.47
▸ PARP1 P09874 1/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ RPS6KA3 P51812 1/20 0.47
▸ HTR1A P08908 2/20 0.44
▸ ADRA1D P25100 2/20 0.44
▸ ADRA1A P35348 2/20 0.44
▸ ADRA1B P35368 2/20 0.44
▸ KDR P35968 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NQO2 P16083 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ EGFR P00533 4/20 0.38
▸ CSF1R P07333 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6956273 0.83 HTT (0.53) PARP1HTR1AADRA1DADRA1AADRA1B
SCHEMBL19044344 0.79 EGFR (0.39) PARP1EGFR
SCHEMBL12143429 0.79 MPO (0.45) KDRHTTEGFRCSF1RMAP4K4
SCHEMBL13783329 0.79 RXFP1 (0.49) HTTKDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL31469313 0.79 MPO (0.45) KDRHTTKDM4EMAPK1ALDH1A1
SCHEMBL856083 0.79 PDE4A (0.53) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL20470720 0.79 CHEK1 (0.44) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL7376295 0.79 MAP4K4 (0.54) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL14579633 0.79 CHEK1 (0.44) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL21347904 0.76 CHEK1 (0.42) CHEK1PARP1PIM1RPS6KA3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS PLIANT THERAPEUTICS INC (US) 2023-09-21 — — US disclosed
US-11744146-B2 Amine-based compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-29 — — US disclosed
WO-2022226349-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA, INC. (CA) 2022-10-27 — — WO disclosed
WO-2021254493-A1 CYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF 上海翊石医药科技有限公司 2021-12-23 — — WO disclosed
WO-2021155321-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
US-11059804-B2 Protein kinase C inhibitors and methods of their use NOVARTIS AG (CH) 2021-07-13 — — US disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 — — WO disclosed
US-10249830-B2 Carbazole-based compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2019-04-02 — — US disclosed
US-20180226579-A1 AMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2018-08-09 — — US disclosed
EP-2218716-A1 METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND Nissan Chemical Industries, Ltd. (JP) 2010-08-18 — — EP disclosed
US-20100056517-A1 ARYLSULFONAMIDE COMPOUNDS GENENTECH, INC. (US) 2010-03-04 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 — — US disclosed
US-7557113-B2 Substituted pyrrolo[3,2-d]pyrimidine derivatives TEIJIN PHARMA LIMITED (JP) 2009-07-07 — — US disclosed
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 — — US disclosed
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10249830-B2 Carbazole-based compound and organic light-emitting device including the same OCIAD1, OXA1L, OCIAD2 CHEK1 1411/4885PARP1 91/4885PIM1 435/4885
US-20180226579-A1 AMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AOC2, AOC1, EML4 CHEK1 1744/4885PARP1 1926/4885PIM1 2084/4885
US-20230293519-A1 INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS ITGB6, ITGA5, ITGAV CHEK1 4304/4885PARP1 1496/4885PIM1 1498/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET CHEK1 1033/4885PARP1 1824/4885PIM1 580/4885
US-11059804-B2 Protein kinase C inhibitors and methods of their use PRKCA, PRKCB, PRKCH CHEK1 144/4885PARP1 1425/4885PIM1 275/4885
US-20100056517-A1 ARYLSULFONAMIDE COMPOUNDS BCL2A1, BCL2, BAX CHEK1 1435/4885PARP1 1381/4885PIM1 401/4885
US-11744146-B2 Amine-based compound and organic light-emitting device including the same AOC2, AOC1, EML4 CHEK1 1744/4885PARP1 1926/4885PIM1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.